Registrieren
Registierung erfolgt in Kürze...
Details werden geladen...
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the ...
BH-30643 has demonstrated encouraging clinical activity against diverse EGFR genotypes and on-target resistance in heavily pretreated Phase 1 dose escalation/backfill population with advanced EGFR-mutant NSCLC
Ähnliche Seiten
Remix Therapeutics Announces Positive Data from Phase 1/2 ARIA Study of First-in-Class MYB mRNA Degrader, REM-422, in Patients with Adenoid Cystic Carcinoma (ACC) at the American Society of Clinical ...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/remix-therapeutics-announces-positive-data-from-phase-12-aria-study-of-first-in-class-myb-mrna-degrader-rem-422-in-patients-with-adenoid-cystic-carcinoma-acc-at-the-american-society-of-clinical-oncology-annual-meeting-2026/2349708HiberCell to Present Preliminary Results from the Phase 1b Trial of GCN2 Activator HC-7366 when Combined with WELIREG® (belzutifan) for the Treatment of Late-Line Clear Cell Renal Cell Carcinoma (ccR...
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/hibercell-to-present-preliminary-results-from-the-phase-1b-trial-of-gcn2-activator-hc-7366-when-combined-with-welireg-belzutifan-for-the-treatment-of-late-line-clear-cell-renal-cell-carcinoma-ccrcc-at-the-upcoming-2026-asco-annual-meeting/2349697Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy | The Manila Times
https://www.manilatimes.net/2026/05/19/tmt-newswire/media-outreach-newswire/amplexd-therapeutics-initiates-phase-2-clinical-trial-of-investigational-egcg-based-hpv-therapy/2346685Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/microbiotica-announces-positive-results-from-its-phase-1b-trial-melody-1-of-mb097-a-precision-microbiome-co-therapy-in-advanced-melanoma/2345933SEED Therapeutics to Present Phase 1 Trial Design for ST-01156, a First-in-Human Oral RBM39 Molecular Glue Degrader, at 2026 ASCO Annual Meeting | The Manila Times
https://www.manilatimes.net/2026/05/18/tmt-newswire/globenewswire/seed-therapeutics-to-present-phase-1-trial-design-for-st-01156-a-first-in-human-oral-rbm39-molecular-glue-degrader-at-2026-asco-annual-meeting/2346087